RADIO IMMUNOASSAY KITS FOR PLATELET ACTIVATING FACTOR

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$50,000.00
Award Year:
1988
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Agency Tracking Number:
8052
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Biomol Research Laboratories
5166 Campus Dr, Plymouth Meeting, PA, 19462
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
() -
Business Contact:
() -
Research Institution:
n/a
Abstract
THE GOAL OF THE PROPOSED RESEARCH IS TO DEVELOP A HIGHLY SENSITIVE AND SPECIFIC RADIOIMMUNOASSAY FOR PLATELET ACTIVATING FACTOR (PAF). PAF IS A LIPID MEDIATOR PRODUCED BY A VARIETY OF INFLAMMATORY CELLS SUCH AS NEUTROPHILS, PLATELETS, MACROPHAGES, EOSINOPHILS, AND VASCULAR ENDOTHELIAL CELLS. PAF INDUCES A NUMBER OF IN VIVO EFFECTS INCLUDING ACUTE BRONCHOCONSTRICTION AND BRONCHOPULMONARY HYPERREAC-TIVITY ACCOMPANIED BY PLATELET, EOSINOPHIL, AND MACROPHAGE ACTIVATION AND RECRUITMENT. THUS THE ROLE OF PAFIN THE PATHOPHYSIOLOGY OF IMMEDIATE HYPERSENSITIVITY REACTIONS, ESPECIALLY ASTHMA, AND INFLAMMATION IS APPARENT. SPECIFIC AIMS INCLUDE: 1) PREPARATION OF A METABOLICALLY STABLE PAF DERIVATIVE SUITABLY FUNCTIONALIZED FOR PROTEIN CONJUGATION, 2) PREPARATION OF A PAF-PROTEIN CONJUGATE. 3) PRODUCTION OF ANTIBODIES TO THE CONJUGATE BY IMMUNIZATION OF RABBITS, 4) PRODUCTION OF PAF RADIOIMMUNOASSAY KITS FOR COMMERCIAL-IZATION. A LARGE NUMBER OF PHARMACEUTICAL COMPANIES ARE DEVELOPING NOVEL AND MORE SPECIFIC THERAPEUTIC AGENTS BASED ON PAF INHIBITION OR ANTAGONISM AND THESE KITS ARE EXPECTED TO FIND WIDE APPLICATION.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government